RA PHARMACEUTICALS INC's ticker is RARX and the CUSIP is 74933V108. A total of 151 filers reported holding RA PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is 16.18 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $52,660,000 | +590.7% | 1,096,869 | +575.2% | 0.04% | +950.0% |
| Q4 2019 | $7,624,000 | +1575.6% | 162,443 | +744.9% | 0.00% | – |
| Q3 2019 | $455,000 | -69.7% | 19,226 | -61.5% | 0.00% | -100.0% |
| Q2 2019 | $1,502,000 | +135.8% | 49,959 | +75.8% | 0.00% | – |
| Q1 2019 | $637,000 | +57.3% | 28,411 | +27.6% | 0.00% | – |
| Q4 2018 | $405,000 | -19.3% | 22,263 | -19.7% | 0.00% | – |
| Q3 2018 | $502,000 | +924.5% | 27,742 | +450.9% | 0.00% | – |
| Q2 2018 | $49,000 | +22.5% | 5,036 | -33.2% | 0.00% | – |
| Q1 2018 | $40,000 | -21.6% | 7,534 | +27.0% | 0.00% | – |
| Q4 2017 | $51,000 | -65.8% | 5,932 | -41.7% | 0.00% | – |
| Q3 2017 | $149,000 | +28.4% | 10,177 | +64.5% | 0.00% | – |
| Q2 2017 | $116,000 | +61.1% | 6,185 | +83.5% | 0.00% | – |
| Q1 2017 | $72,000 | +38.5% | 3,370 | -3.1% | 0.00% | – |
| Q4 2016 | $52,000 | – | 3,479 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Novo Holdings A/S | 2,031,562 | $17,268,000 | 2.42% |
| NEA Management Company, LLC | 3,493,636 | $29,696,000 | 1.23% |
| VHCP Management II, LLC | 544,612 | $4,629,000 | 1.11% |
| RA Capital Management | 1,351,808 | $11,490,000 | 0.96% |
| Rock Springs Capital Management LP | 600,000 | $5,100,000 | 0.23% |
| Rhenman & Partners Asset Management AB | 108,451 | $922,000 | 0.12% |
| Tekla Capital Management LLC | 356,237 | $3,028,000 | 0.12% |
| ELLINGTON MANAGEMENT GROUP LLC | 34,900 | $297,000 | 0.05% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 79,150 | $673,000 | 0.03% |
| Candriam S.C.A. | 151,000 | $1,284,000 | 0.02% |